- •We evaluated the effect of smoking on the efficacy of oral DMDs in MS patients.
- •Current smoking was a risk factor for relapse in MS patients under oral DMDs.
- •Disease course of former-smokers was similar to that of never-smokers.
- •MS patients should be advised to stop smoking even after initiation of oral DMDs.
In relapsing-remitting multiple sclerosis (RRMS), smoking is a known risk factor for disease susceptibility and disability progression. However, its impact on the efficacy of oral disease-modifying drugs (DMDs) is unclear. Therefore, we initiated a single-center, retrospective, observational study to investigate the relationship between smoking and disease activity in RRMS patients under oral DMDs.
We retrospectively enrolled RRMS patients who initiated oral DMDs (fingolimod or dimethyl fumarate) at our hospital between January 2012 and December 2019. Clinical data and smoking status at oral DMD initiation were collected up to December 2020. We conducted survival analyses for relapse and any disease activity, defined as relapse or MRI disease activity, among patients with distinct smoking statuses.
We enrolled 103 RRMS patients under oral DMDs including 19 (18.4%) current smokers at baseline. Proportions of relapses and any disease activity during follow-up were higher in current smokers (relapse: p = 0.040, any disease activity: p = 0.004) and time from initiating oral DMDs to relapse was shorter in current smokers (log-rank test: p = 0.011; Cox proportional hazard analysis: hazard ratio (HR) 2.72 [95% confidence interval (CI) 1.22–6.09], p = 0.015) than in non-smokers. Time from initiating oral DMDs to any disease activity was also shorter in current smokers (log-rank test: p = 0.016; Cox proportional hazard analysis: HR 2.18 [95% CI 1.14–4.19], p = 0.019) than in non-smokers. The survival curves for relapse and any disease activity were not different between the former smoker and never-smoker groups. Multivariate survival analysis showed current smoking was an independent risk factor for relapse or any disease activity after adjusting for covariates (relapse: HR 2.54 [95% CI 1.06–6.10], p = 0.037; any disease activity: HR 3.47 [95% CI 1.27–9.50], p = 0.015).
Smoking was a risk factor for disease activity in RRMS patients under oral DMD treatment. RRMS patients should be advised to stop smoking even after the initiation of DMDs.
Abbreviations:ARR (annualized relapse rates), CI (confidence intervals), CSF (cerebrospinal fluid), DMD (disease modifying drug), DMF (dimethyl fumarate), EDSS (Kurtzke's expanded disability status scale), FTY (fingolimod), GA (glatiramer acetate), HR (hazard ratio), IFN-β (interferon-beta), IQR (interquartile range), MS (multiple sclerosis), MSSS (multiple sclerosis severity score), NEDA (no evidence of disease activity), NOx (nitrogen oxide), OCBs (oligoclonal IgG bands), PSL (prednisolone), RRMS (relapsing-remitting multiple sclerosis), SPMS (secondary progressive multiple sclerosis)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- A population-based study of multiple sclerosis in twins: update.Ann. Neurol. 1993; 33: 281-285https://doi.org/10.1002/ana.410330309
- Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis.Nat. Rev. Neurol. 2017; 13: 25-36https://doi.org/10.1038/nrneurol.2016.187
- Environmental risk factors for multiple sclerosis in Japanese people.Mult. Scler. Relat. Disord. 2020; 38101872https://doi.org/10.1016/j.msard.2019.101872
- Cigarette smoking and the progression of multiple sclerosis.Brain. 2005; 128: 1461-1465https://doi.org/10.1093/brain/awh471
- Smoking and multiple sclerosis: a systematic review and meta-analysis using the Bradford Hill criteria for causation.Mult. Scler. Relat. Disord. 2017; 17: 207-216https://doi.org/10.1016/j.msard.2017.07.020
- Early predictors of conversion to secondary progressive multiple sclerosis.Mult. Scler. Relat. Disord. 2021; 54103115https://doi.org/10.1016/j.msard.2021.103115
- No association of tobacco use and disease activity in multiple sclerosis.Neurol. Neuroimmunol. NeuroInflammation. 2016; 3: e260https://doi.org/10.1212/NXI.0000000000000260
- The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis.Mult. Scler. Relat. Disord. 2021; 49102773https://doi.org/10.1016/j.msard.2021.102773
- Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.Mult. Scler. J. Exp. Transl. Clin. 2020; 62055217320959815https://doi.org/10.1177/2055217320959815
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.Lancet Neurol. 2018; 17: 162-173https://doi.org/10.1016/S1474-4422(17)30470-2
- Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology. 1983; 33: 1444-1452https://doi.org/10.1212/wnl.33.11.1444
- Multiple sclerosis severity score: using disability and disease duration to rate disease severity.Neurology. 2005; 64: 1144-1151https://doi.org/10.1212/01.WNL.0000156155.19270.F8
- Fingolimod rebound: a review of the clinical experience and management considerations.Neurol. Ther. 2019; 8: 241-250https://doi.org/10.1007/s40120-019-00160-9
- Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis.Mult. Scler. 2016; 22: 1297-1305https://doi.org/10.1177/1352458515616701
- Smoking and multiple sclerosis: an updated meta- analysis.PLoS One. 2011; 6: e16149https://doi.org/10.1371/journal.pone.0016149
- Smoking and disease progression in multiple sclerosis.Arch. Neurol. 2009; 66: 858-864https://doi.org/10.1001/archneurol.2009.122
- Smoking worsens multiple sclerosis prognosis: two different pathways are involved.J. Neuroimmunol. 2015; 281: 23-34https://doi.org/10.1016/j.jneuroim.2015.03.006
- T cells become licensed in the lung to enter the central nervous system.Nature. 2012; 488: 675-679https://doi.org/10.1038/nature11337
- Impacts of cigarette smoking on immune responsiveness: up and down or upside down?.OncoTargets Ther. 2017; 8: 268-284https://doi.org/10.18632/oncotarget.13613
- CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.Neurology. 2004; 63: 1439-1445https://doi.org/10.1212/01.wnl.0000142043.32578.5d
- Glutamate and Nitric Oxide as biomarkers for disease activity in patients with multiple sclerosis.Mult. Scler. Relat. Disord. 2020; 38101873https://doi.org/10.1016/j.msard.2019.101873
- Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.Ann. Neurol. 2014; 76: 325-337https://doi.org/10.1002/ana.24217
- Smoking affects the interferon beta treatment response in multiple sclerosis.Neurology. 2018; 90: e593-e600https://doi.org/10.1212/WNL.0000000000004949
- Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.Mult. Scler. 2019; 25: 1298-1305https://doi.org/10.1177/1352458518791753
- Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta.J. Neurol. 2010; 257: 1703-1707https://doi.org/10.1007/s00415-010-5606-4
- Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a.Mult. Scler. 2014; 20: 445-450https://doi.org/10.1177/1352458513498635
- Smokers run increased risk of developing anti-natalizumab antibodies.Mult. Scler. 2014; 20: 1081-1085https://doi.org/10.1177/1352458513515086
- Genetic and Infectious Profiles of Japanese Multiple Sclerosis Patients.PLoS One. 2012; 7: e48592https://doi.org/10.1371/journal.pone.0048592
- Multiple sclerosis in Japan appears to be a milder disease compared to the UK.J. Neurol. 2015; 262: 831-836https://doi.org/10.1007/s00415-015-7637-3
- Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey.J. Neurol. Sci. 2009; 280: 22-28https://doi.org/10.1016/j.jns.2009.01.008
Published online: January 09, 2023
Accepted: January 9, 2023
Received in revised form: November 22, 2022
Received: June 15, 2022
© 2023 Elsevier B.V. All rights reserved.